Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Megestrol · 2 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| Megestrol acetate | DRUG | - |
Inclusion Criteria Patient must have: * Confirmed diagnosis of AIDS (CDC definition). * Documented weight loss or anorexia. * Life expectancy = or \> 20 weeks. * The perception that the weight loss is a detriment to their well-being. * Ability to provide informed consent, read and write English. ...
Megestrol is a small molecule being developed for anorexia, a condition of appetite loss. It is also studied in patients with cachexia and HIV infections. The drug is currently in Phase 3 clinical development, though the specific trials listed are completed.
Megestrol is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical trials for the drug in the United States, focusing on anorexia and related conditions.
Megestrol is in Phase 3 clinical development for anorexia. The drug has completed two trials, including a Phase 3 study and a Phase 2 study, both in patients with anorexia and cachexia associated with HIV infections.
Megestrol has two completed clinical trials. NCT00002067 is a Phase 3 study comparing megestrol acetate at 800 mg/day with placebo in AIDS patients with anorexia and cachexia. NCT00002300 is a Phase 2 study of different doses in AIDS patients with anorexia and malnutrition.
Megestrol is a small molecule, but its specific molecular target is not provided. It is being studied for its effects on anorexia and cachexia, particularly in patients with HIV infections, though the exact mechanism of action is not detailed.